Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
National Hemophilia Foundation
Jennifer Maahs, RN, PNP, MSN
Indiana Hemophilia and Thrombosis Center
Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.
Hemophilia Quick Facts
- Hemophilia prevalence rates are low with only 11 patients per 100,000 in a commercial population for hemophilia A and 21 patients per 100,000 in a Medicaid population.
- The prevalence rate of inhibitors, one of the most serious complications, is 2% - 9% for hemophilia A and 1% - 4% for hemophilia B.
- Inhibitors typically develop early in life in patients with severe hemophilia A or B: the median age is 1.7 – 3.3 years.
- The greatest risk for inhibitor development occurs within the first 50 days of exposure to factor concentrate.
- Bypassing agents used to treat patients with inhibitors have an unpredictable efficacy of 50% - 90%. Bleeding episodes in patients with an inhibitor is difficult to treat with currently available therapies.